Delcath Systems Uniquely Positioned for the Treatment of Metastatic Liver Cancer With its Hepzato Kit - Craig-Hallum Sees a 30% Potential!
Reading Time: 2 minutes
Delcath Systems (DCTH) has specialized as a medical technology company in effective and regional chemotherapy for the treatment of metastatic liver cancer. In August 2023, the FDA approved the Hepzato Kit as the first targeted and high-dose chemotherapy for the entire liver. This can treat common liver metastases in metastatic uveal melanoma (mUM), presenting a revenue opportunity of 600 million USD in the USA. Based on the Hepatic Delivery System (HDS), Phase 2 studies for mBC (metastatic breast cancer) and mCRC (metastatic colorectal cancer)...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
